Thursday, February 20, 2014
Glioblastoma patients gain no survival benefit from Avastin
Subscribe to:
Post Comments (Atom)
skip to main |
skip to sidebar
MEDPAGE TODAY – Feb. 20, 2014 – A pair of randomized trials
testing the benefits of Avastin added to radiation and chemotherapy for
glioblastoma showed increased progression-free survival but no overall increase
in survival. The studies were published in the Feb. 20, 2014 New England Journal of Medicine.
Labels
- 3D tomosynthesis (1)
- active surveillance (2)
- acute lymphoblastic leukemia (5)
- acute myelogenous leukemia (2)
- Acute myeloid leukemia (3)
- ADC (1)
- adenomas (1)
- afatinib (1)
- ALK (1)
- ALK mutation (1)
- ALL (2)
- alpha-amanatin (1)
- AML (3)
- anastrozole (1)
- androgen deprivation therapy (4)
- anti-angiogenesis (2)
- antibody drug conjugate (1)
- Antioxidant (1)
- APC (1)
- aromatase inhibitors (2)
- Artemisinin (1)
- artesunate (1)
- aspirin (5)
- atrophy (1)
- Avastin (1)
- B-cell ALL (1)
- bacterial markers (1)
- bacterial therapy (2)
- basal cell carcinoma (1)
- benefits (1)
- benign prostate hyperplasia (1)
- beta-blockers (1)
- bevacizumab (1)
- bevicizumab (1)
- bilateral mastectomy (1)
- biomarker (1)
- biomarkers (1)
- biosurgery (1)
- birth control (1)
- bladder cancer (5)
- blinatumomab (2)
- blood test (4)
- Bone cancer (2)
- bone marrow transplant (1)
- bortezomib (1)
- bowel cancer (1)
- BPH (1)
- BRAF inihibitor (1)
- brain cancer (2)
- brain metastases (1)
- bras (1)
- BRCA1 (3)
- BRCA2 (3)
- breast cancer (54)
- breast cancer screening (2)
- breast density (1)
- brentuximab vedotin (1)
- Brg1 (1)
- cachexia (1)
- caffeine (2)
- calcium channel blockers (1)
- cancer (12)
- cancer blood test (1)
- Cancer prevention (2)
- cancer risk (1)
- cancer screening (1)
- cancer surgery (1)
- Cancer treatment (1)
- cancer vaccine (2)
- cardiorespiratory fitness (1)
- cell division (1)
- cervical cancer (2)
- chemoprevention (1)
- chemotherapy (4)
- Chloroquine (1)
- chokeberry (1)
- chronic lymphocytic leukemia (3)
- chronic pain (1)
- cirmtuzumab (1)
- CLL (1)
- clostridium novyi (1)
- CMV (1)
- cobimetinib (1)
- coffee (3)
- Cologuard (1)
- colon cancer (7)
- colon polyps (1)
- colonoscopy (2)
- Colorectal cancer (21)
- contraceptives (1)
- COPD (1)
- copper (1)
- CPX-351 (1)
- CRS-207 (1)
- cryoablation (1)
- CT screening (3)
- ctDNA (1)
- CTLA-4 blockers (1)
- CYRAMZA (2)
- cystine deprivation (1)
- cystoscopy (1)
- cytomegalovirus (1)
- dasatinib (1)
- diabetes (1)
- diagnosis (1)
- DIAPH3 (1)
- diaphanous-related formin-3 (1)
- dietary fiber (1)
- diffuse large B-cell lymphoma (1)
- digital mammography (1)
- docetaxel (1)
- double mastectomy (1)
- early detection (2)
- EGFR (2)
- endocrine therapy (1)
- endometrial cancer (1)
- endoscopic O2 sensor (1)
- epigenetic test (1)
- ER negative (1)
- ER positive breast cancer (1)
- erlotinib (2)
- esophageal cancer (4)
- esophageal squamous cell carcinoma (1)
- estrogen (1)
- exercise (1)
- fallopian tubes (1)
- family history (1)
- fecal DNA test (1)
- Fitness (1)
- fluvestrant (1)
- follicular lymphoma (1)
- gall bladder cancer (1)
- GDF-15 (1)
- gemcitabine (1)
- gene-editing (1)
- genetic mutations (2)
- genetic test (1)
- genomic analysis (1)
- Gilbert's syndrome (1)
- glioblastoma (1)
- glioma (2)
- glutamine (1)
- guanylin (1)
- Gum disease (1)
- GVAX (2)
- HCC (2)
- head and neck cancer (3)
- hematuria (2)
- hepatic tumors (1)
- Hepatitis B (1)
- heptocellular carcinoma (3)
- HER 2 (1)
- HER-2 (1)
- HER2 negative (1)
- HER2+ (1)
- herbal medicine (1)
- Herceptin (1)
- high fat (1)
- high fiber (1)
- Hodgkin lymphoma (1)
- hormone (1)
- hormone blockade (2)
- hormone receptor positive (1)
- hormone therapy (2)
- HOX genes (1)
- HPV (4)
- HPV screen (1)
- HPV vaccine (1)
- HPV16 (1)
- HR+ (1)
- hyperthyroidism (1)
- hypofractionated radiotherapy (1)
- hypothyroidism (1)
- hysterectomy (2)
- ICG (1)
- Imlygic (1)
- immunotherapy (7)
- indoor tanning (1)
- inflammation (1)
- invasive ductal carcinoma (IDC) (1)
- invasive lobular carcinoma (ILC) (1)
- ipilimumab (1)
- Keytruda (1)
- kidney cancer (2)
- LDCT (1)
- lenvatinib (1)
- leukemia (7)
- linaclotide (1)
- liquid biopsies (1)
- listeria (1)
- liver cancer (5)
- liver metastasis (1)
- long (1)
- low-dose CT screening (1)
- lumpectomy mastectomy (1)
- Lung cancer (11)
- lycopene (1)
- lymphoma (5)
- lynch syndrome (1)
- mammography (5)
- mantel cell lymphoma (1)
- MAP3K7-CHD1 mutation (1)
- mass spectrometry (1)
- mastectomy (2)
- MDT (1)
- measles virus (1)
- medical patch (1)
- Medicare Advisory Panel (1)
- Mediterranean diet (1)
- MEK inhibitor (1)
- melanoma (18)
- meningioma (1)
- menthol (1)
- metastasis (3)
- metastatic breast cancer (1)
- metastatic cancer (5)
- metastatic colorectal cancer (1)
- metformin (1)
- mitochondria (1)
- moles (1)
- morcellation (1)
- MPDL3280A antibody (1)
- MRI (1)
- MRI screening (1)
- MRTFs (1)
- multiparametric MRI-US (1)
- multiple myeloma (3)
- multivitamins (1)
- Myosin-10 (1)
- nanoparticles (1)
- near infrared light (1)
- needle biopsy (2)
- neoadjuvant chemotherapy (3)
- nevi (1)
- nicotinamide (1)
- non-coding RNA (1)
- non-Hodgkin lymphoma (3)
- non-small cell lung cancer (8)
- NSAIDs (1)
- nsclc (4)
- NY-ESO-1–specific TCR (1)
- obesity (2)
- olaparib (1)
- olparib (1)
- oncolytic viral therapy (4)
- oral cancer (1)
- Oropharyngeal cancer (4)
- osteosarcoma (1)
- otolaryngology (1)
- ovarian cancer (12)
- ovarian cysts (1)
- p53 (1)
- p66ShcA (1)
- pancreatic cancer (14)
- pancreatice cancer (1)
- Pap test (1)
- paravertabral blocks (1)
- parp inhibitor (2)
- pathologic complete response (1)
- pCR (1)
- PD-1 inhibitor (1)
- pembrolizumab (1)
- pemetrexed (1)
- periodontal disease (1)
- PET-scan (1)
- photoacoustics (1)
- photoimmunotherapy (1)
- postmenopausal (1)
- PR negative (1)
- prenatal screening (1)
- probiotic bacteria (1)
- prophylactic mastectomy (2)
- prostate (2)
- prostate biopsy (2)
- Prostate cancer (41)
- prostate cancer test (2)
- prostate diagnosis (1)
- prostate specific antigen (3)
- prostatectomy (4)
- Provenge (1)
- PSA (6)
- PSA screen (1)
- PSA test (1)
- radiation (1)
- radiation therapy (4)
- radio frequency ablation (1)
- radiotherapy (1)
- raloxifene (1)
- ramucirumab (2)
- rectal cancer (1)
- Renal cell carcinoma (1)
- resveratrol (1)
- RNA test for cancer (1)
- robot-assisted radical prostatectomy (2)
- ROR1 (1)
- salpingectomy (1)
- salvage radiation therapy (1)
- sargramostim (1)
- screening (4)
- seed implants (1)
- sildenafil (1)
- skin cancer (6)
- smoking (1)
- SNPs (1)
- sonodynamic therapy (1)
- Sprycel (1)
- squamous cell carcinoma (1)
- stem cells (1)
- stomach cancer (4)
- sulforphane (1)
- surgery (3)
- T-cell prolymphocytic leukemia (1)
- T-cell therapy (2)
- T-cell transfer therapy (1)
- T. gondii (1)
- tamoxifen (3)
- tanning beds (2)
- targeted MRI biopsy (1)
- targeted therapy (3)
- TAS-102 (1)
- taxoplasma gondii (1)
- Taxotere (1)
- Tecentriq (1)
- testosterone (1)
- thyroid (1)
- thyroid cancer (1)
- TNBC (1)
- tobacco (1)
- tomatoes (1)
- trastuzumab (1)
- Trebananib (1)
- trichloroacetic acid (1)
- triple negative breast cancer (1)
- tumor targeting agent (1)
- tyrosine kinase inhibitors (1)
- U.S. Preventive Services Task Force (1)
- ultrasound (2)
- ultrasound screening (1)
- urethial carcinoma (1)
- USPTF (2)
- uterine cancer (1)
- uterine fibroids (1)
- value (1)
- vasectomy (1)
- vegetarian (1)
- Velcade (1)
- vemurafenib (1)
- Venclexta (1)
- venetoclax (2)
- venom therapy (1)
- viagra (1)
- Video of how treatment is done. (1)
- viral therapy (2)
- virotherapy (1)
- vitamin B3 (1)
- vitamin D (3)
- waist size (1)
- war metaphor (1)
- wasting (1)
- watchful waiting (3)
- women smoking (1)
- young adult onset (1)
Seattle Health News
Powered by Blogger.
Subscribe to CancerDigest
Curated cancer news in your email inbox.
Feedly
Blog Archive
Followers
About Me
- Michael O'Leary
- More than ever, the connections you make and maintain with your patients, providers and staff are the keys to success. We have experience providing health care content in support of your relationship marketing. We help you provide the content that serves your patients' and providers' needs.
No comments:
Post a Comment